Melanoma (Treatment)

Virulizin Marketing Approval Filed in Mexico To Treat Cancer

Published in Cancer Weekly, December 9th, 1996

Imutec Corp., Toronto, Ontario, Canada, announced that it has submitted an application for product registration of Virulizin with the SSA (Ministry of Health, Mexico) for the treatment of malignant melanoma.

The application is based on the results of a Phase II clinical trial in 51 patients with advanced disease which was completed in 1993 under the supervision of Dr. Jaime de la Garza, National Cancer Institute. The results from that trial demonstrated that Virulizin provided patient benefit through improvements in survival and quality of life.

"We are very pleased to be taking this first step towards the commercialization of Virulizin," said...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1996-12-09)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry